Holen Sie sich die Stockscreener-App
91.84
0.21%
0.19
Vorhandelsmarkt:
91.83
-0.01
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$91.65
Offen:
$92.01
24-Stunden-Volumen:
6.45M
Relative Volume:
1.06
Marktkapitalisierung:
$114.43B
Einnahmen:
$28.30B
Nettoeinkommen (Verlust:
$126.00M
KGV:
1,020.44
EPS:
0.09
Netto-Cashflow:
$9.43B
1W Leistung:
+2.18%
1M Leistung:
-1.03%
6M Leistung:
+25.29%
1J Leistung:
+6.20%
1-Tages-Spanne:
$91.69
$92.80
1-Wochen-Bereich:
$89.02
$93.07
52-Wochen-Spanne:
$62.07
$98.90
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
91.84 | 114.43B | 28.30B | 126.00M | 9.43B | 0.09 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Merit Financial Group LLC Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Can Gilead Sciences Sustain Its Growth Momentum In 2025? - Barchart
Can Gilead Sciences Sustain Its Growth Momentum in 2025? - Yahoo Finance
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults - PMLiVE
HB Wealth Management LLC Purchases 8,406 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Gilead Sciences Q2 EPS Estimate Boosted by Zacks Research - MarketBeat
Liberty One Investment Management LLC Sells 7,350 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Nexus Investment Management ULC Trims Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Premier Path Wealth Partners LLC Has $744,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Arkadios Wealth Advisors Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Boston Common Asset Management LLC Sells 53,301 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Wedge Capital Management L L P NC Sells 86,409 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Park Avenue Securities LLC Buys 6,878 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Avanza Fonder AB Takes $11.74 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $228,375.00 in Stock - MarketBeat
Advanced biologic developer Gilead cites manufacturing efficiencies as CAR-T advantage in 2025 - BioProcess Insider
Gilead Sciences CFO sells shares worth $228,375 - MSN
Earnings Preview: What to Expect From Gilead Sciences’ Report - Nasdaq
Earnings Preview: What To Expect From Gilead Sciences’ Report - Barchart
Occidental Asset Management LLC Acquires 3,980 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Trimmed by Sicart Associates LLC - MarketBeat
Gateway Investment Advisers LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Global Pharma & Biotech CRM Software Market To Surpass Valuation of US$ 20.0 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences - Yahoo Finance
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus.com
Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others - Yahoo Finance
Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy? - Insider Monkey
Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy - FiercePharma
Gilead, US Settle Billion-Dollar Patent Feud Over HIV Drugs (1) - Bloomberg Law
Gilead's Kite taps longtime Amgen alum as new global commercial head - FiercePharma
JPM25 Day 3: AbbVie, Gilead, GSK and Dyne - BioSpace
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - Yahoo Finance
JPM Day 3: AbbVie, Gilead, GSK and Dyne - BioSpace
Rovin Capital UT ADV Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
USA Financial Formulas Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Primary Sclerosing Cholangitis Market Deep Research Report Forecast by 2031 | Acorda Therapeutics, Inc., - EIN News
Gilead And US Settle HIV Drug Patent Dispute - Finimize
Assenagon Asset Management S.A. Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead, Feds Resolve HIV Drug Patent Dispute Amid Appeal - Law360
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance
Gilead reportedly settles CDC patent dispute over HIV drugs - Seeking Alpha
Gilead Sciences Inc. stock rises Wednesday, still underperforms market - MarketWatch
Biden administration and Gilead settle long-running battle over patents for HIV PrEP pills - STAT
Gilead Sciences, US government settle patent case over HIV prevention drugs - MSN
Autologous Cell Therapy Market Set to Witness Significant Growth by 2025-2032: Bristol Myers Squibb, Gilead - EIN News
40 Under 40: Rasika Iyer, Gilead Sciences - MM+M Online
April 17th Options Now Available For Gilead Sciences (GILD) - Nasdaq
Global Financial Private Client LLC Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Wright Investors Service Inc. Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):